Integra Lifesciences Holdings Corp (IART) Company Profile & Statistics

Integra Lifesciences Holdings Corp
IART
(Nasdaq - US)
N/A
28.98
+0.64 (+2.26%)
in:usd•As of: Apr 29, 2024 10:05 UTC -4
Open
28.48
High
28.98
Low
28.48

About Integra Lifesciences Holdings Corp

CEO

Jan De Witte

Headquarters

1100 campus road

princeton, nj 08540, united states

Auditor

PricewaterhouseCoopers LLP

Employees

3,946

Share Holders

749

Website

www.integralife.com

Industry

medical specialties

Sector

health technology

Company Overview

Integra LifeSciences is one of the world leaders in regenerative medicine. The company develops, manufactures and markets cost-effective surgical implants and medical instruments. The company now manufactures and sells products in the following two global reportable business segments: Codman Specialty Surgical (CSS) and Orthopedics and Tissue Technologies (OTT). The CSS business offers global, market-leading technologies, brands and instrumentation. The global commercial network includes clinical specialists, a large direct global sales force and strategic partnerships and distributors that serve hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers and health care providers in North America, South America, Europe, Asia Pacific, Middle East and Africa. The Tissue Technologies segment includes wound reconstruction and repair products, bone grafts and nerve and tendon repair products.

Integra Lifesciences Holdings Corp Statistics

Valuation Measures

Market Capitalization ²	2.28B
Enterprise Value	3.50B
Enterprise Value/EBITDA (ttm)	14.51
Price to Earnings Ratio (ttm)	9.14
Price to Book (mrq)	1.40
Price to Sales (ttm)	1.45
Price to Cash (ytd)	5.87

Profitability

Gross Margin (ttm)	57.40%
Operating Margin (ttm)	16.07%
Profit Margin (ttm)	4.39%
Return on Equity (ttm)	15.19%
Return on Invested Capital (ttm)	2.21%
Return on Assets (ttm)	6.59%

Income Statement

Revenue (ttm)	1.54B
Revenue Per Share (ttm)	19.71
Gross Profit (ttm)	884.74M
EBITDA (ttm)³	241.20M
Net Income Avi to Common (ttm)	67.74M
Diluted EPS (ttm)	0.83

Share Statistics

Beta (5Y Monthly)	1.12
52-Week Change	-47.91%
S&P500 52-Week Change	26.00%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	78.22M
Dividend Yield	0.00%
Float ⁴	76.17M
% Held by Insiders	3.10%
% Held by Institutions	84.78%

Balance Sheet

Total Cash (mrq)	309.10M
Total Cash Per Share (mrq)	3.95
Total Debt (mrq)	1.50B
Total Debt/Equity (mrq)	94.44%
Current Ratio (mrq)	3.45%
Quick Ratio (mrq)	2.18%
Book Value Per Share (mrq)	20.31

Cash Flow

Operating Cash Flow Per Share (ytd)	1.74
Free Cash Flow (ytd)	73.09M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Integra Lifesciences Holdings Corp

Trade With A Regulated Broker